ESMOASIA24,blcsm,oncology

Mashup Score: 2

Durvalumab Plus Vaccine Therapy Elicits ‘Encouraging’ DFS in BCG-Unresponsive NMIBC - 17 hour(s) ago

Durvalumab plus vaccine therapy demonstrated evidence of preliminary antitumor activity without substantial additive toxicity in BCG-unresponsive NMIBC.

Source: www.onclive.com

Categories: General Medicine News, Oncologists1

Tweet Tweets with this article
- OncLive
  
  Durvalumab Plus Vaccine Therapy Elicits ‘Encouraging’ DFS in BCG-Unresponsive NMIBC @myESMO #ESMOASIA24 #blcsm #oncology https://t.co/IB8mnytOXN